A Phase1 Study of VIB9600

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions
Safety Issues
Interventions
BIOLOGICAL

VIB9600

"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."

DRUG

Placebos

Placebo administered by slow IV infusion or SC injection.

Trial Locations (1)

45212

CTI Clinical Trial & Consulting Clinical Research Center, Cincinnati

Sponsors
All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

Amgen

INDUSTRY